Search

Your search keyword '"Lint, Mt"' showing total 435 results

Search Constraints

Start Over You searched for: Author "Lint, Mt" Remove constraint Author: "Lint, Mt"
435 results on '"Lint, Mt"'

Search Results

151. Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation.

153. Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors.

154. Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update.

155. DLI after haploidentical BMT with post-transplant CY.

156. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.

157. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.

158. CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation.

159. Systemic lupus erythematosus complicated with thymoma and pure red cell aplasia (PCRA). CR of both complications following thymectomy and allogeneic haematopoietic SCT (HSCT), but persistence of antinuclear antibodies (ANA).

160. [Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation].

161. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R.

162. Sjögren's syndrome associated chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) treated with autologous and subsequently allogeneic haematopoietic SCT (HSCT).

163. Paternity wishes in long-term survivors after allogeneic hematopoietic SCT. A study of the late effects working party of the EBMT.

164. Increase of suicide and accidental death after hematopoietic stem cell transplantation: a cohort study on behalf of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

165. Ongoing graft-versus-host disease is a risk factor for azoospermia after allogeneic hematopoietic stem cell transplantation: a survey of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation.

166. Standard treatment of acquired SAA in adult patients 18-40 years old with an HLA-identical sibling donor.

167. Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression.

168. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.

169. Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients.

170. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.

171. In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT.

172. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.

173. Persistence of a positive (1,3)-beta-D-glucan test after clearance of candidemia in hematopoietic stem cell transplant recipients.

174. Helical tomotherapy targeting total bone marrow after total body irradiation for patients with relapsed acute leukemia undergoing an allogeneic stem cell transplant.

175. Risk factors for enterococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients.

176. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party.

177. Outcome of allogeneic stem cell transplantation following reduced-intensity conditioninig regimen in patients with idiopathic myelofibrosis: the g.I.T.m.o. Experience.

178. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type.

179. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study.

180. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants.

181. Retrospective survey on the prevalence and outcome of prior autoimmune diseases in patients with aplastic anemia reported to the registry of the European group for blood and marrow transplantation.

182. Changes in cytokine profile pre- and post-immunosuppression in acquired aplastic anemia.

183. Autologous haematopoietic stem-cell transplantation in multiple sclerosis: benefits and risks.

184. Late complications after hematopoietic stem cell transplantation.

185. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients.

186. Outbreak of Ralstonia pickettii bacteraemia in patients with haematological malignancies and haematopoietic stem cell transplant recipients.

187. NOLA1 gene mutations in acquired aplastic anemia.

188. Changes in lung volumes and airway responsiveness following haematopoietic stem cell transplantation.

189. Advanced mast cell disease: an Italian Hematological Multicenter experience.

190. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD.

191. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

192. Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk?

193. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

194. Mast cell leukemia: a report of ten cases.

195. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia.

196. Thiotepa-based reduced intensity conditioning regimen: a 10 year follow up.

197. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne.

198. Autologous stem cell transplantation for severe autoimmune diseases: a 10-year experience.

199. Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant.

200. Treatment of refractory chronic GVHD with rituximab: a GITMO study.

Catalog

Books, media, physical & digital resources